EP 2667874 A4 20140730 - INHIBITORS OF MTOR KINASA AS ANTI- VIRAL AGENTS

Title (en)

INHIBITORS OF MTOR KINASA AS ANTI- VIRAL AGENTS

Title (de)

MTOR-KINASE-HEMMER ALS ANTIVIRUSMITTEL

Title (fr)

INHIBITEURS DE KINASE MTOR EN TANT QU'AGENTS ANTIVIRAUX

Publication

EP 2667874 A4 20140730 (EN)

Application

EP 12739403 A 20120127

Priority

US 201161436970 P 20110127
US 2012023035 W 20120127

Abstract (en)

[origin: WO2012103524A2] The present invention provides methods for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR. The invention also provides methods for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR and modulators of the unfolded protein response.

IPC 8 full level

A61K 31/5377 (2006.01)

CPC (source: EP US)

A61K 31/192 (2013.01 - EP US); A61K 31/437 (2013.01 - EP US); A61K 31/4745 (2013.01 - US); A61K 31/496 (2013.01 - EP US); A61K 31/519 (2013.01 - EP US); A61K 31/53 (2013.01 - EP US); A61K 31/5377 (2013.01 - EP US); A61K 31/5386 (2013.01 - US); A61K 31/575 (2013.01 - EP US); A61K 45/06 (2013.01 - EP US); A61P 31/12 (2017.12 - EP); A61P 31/22 (2017.12 - EP); A61P 43/00 (2017.12 - EP)

C-Set (source: EP US)

Citation (search report)

[Y] WO 2009143317 A1 20091126 - WYETH CORP [US], et al
[Y] WO 2008103636 A1 20080828 - NOVARTIS AG [CH], et al
[YP] WO 2011011716 A1 20110127 - UNIV PRINCETON [US], et al
[A] WO 2010124618 A1 20101104 - INST BASIC MED SCIENCES PLA [CN], et al
[A] WO 02088124 A2 20021107 - SMITHKLINE BEECHAM CORP [US], et al
[A] EP 0253412 A2 19880120 - CESKOSLOVENSKA AKADEMIE VED [CS], et al
[Y] VENKATESAN A M ET AL: "PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 19, 1 October 2010 (2010-10-01), pages 5869 - 5873, XP027273580, ISSN: 0960-894X, [retrieved on 20100908]
[Y] DAVID J. RICHARD ET AL: "Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3K[alpha]", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 8, 1 April 2010 (2010-04-01), pages 2654 - 2657, XP055123306, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2010.02.029
[Y] ARANAPAKAM M VENKATESAN ET AL: "Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5'Triphosphate Competitive Phospahtidylinositol-3-kinase/ Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 53, no. 6, 25 March 2010 (2010-03-25), pages 2636 - 2645, XP002666023, ISSN: 0022-2623, [retrieved on 20100218], DOI: 10.1021/JM901830P
[Y] N. J. MOORMAN ET AL: "Rapamycin-Resistant mTORC1 Kinase Activity Is Required for Herpesvirus Replication", JOURNAL OF VIROLOGY, vol. 84, no. 10, 24 February 2010 (2010-02-24), pages 5260 - 5269, XP055053336, ISSN: 0022-538X, DOI: 10.1128/JVI.02733-09
See references of WO 2012103524A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2012103524 A2 20120802; WO 2012103524 A3 20120920; WO 2012103524 A8 20130912; CA 2825825 A1 20120802; EA 201300867 A1 20140331; EP 2667874 A2 20131204; EP 2667874 A4 20140730; JP 2014505076 A 20140227; US 2014206678 A1 20140724

DOCDB simple family (application)

US 2012023035 W 20120127; CA 2825825 A 20120127; EA 201300867 A 20120127; EP 12739403 A 20120127; JP 2013551397 A 20120127; US 201213982331 A 20120127